Please assess the completion status of the following clinical trial:

Trial Title: Apatinib for Inoperable Advanced Chondrosarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1) histologically confirmed high-grade sarcoma;~* 2) initial treatment in the orthopedic oncology departments of the two affiliated hospitals of Peking University;~* 3) tumors not amenable to curative treatment or inclusion in clinical trials;~* 4) unresectable local advanced lesions or multiple metastatic lesions that could not be cured by local therapy;~* 5) measurable lesions according to Response Evaluation Criteria for Solid Tumors (RECIST1.1) ;~* 6) Eastern Cooperative Oncology Group performance status 0 or 1;~* 7) acceptable hematologic, hepatic, and renal function.~Exclusion Criteria:~* had central nervous system metastasis;~* had other kinds of malignant tumors at the same time; had cardiac insufficiency or arrhythmia;~* had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine protein ≥ ++ and so on;~* had pleural or peritoneal effusion that needs to be handled by surgical treatment;~* combined with other infections or wounds;~* pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apatinib Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).